Genetic Signatures (ASX:GSS) Short-Term Debt: A$0.47 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genetic Signatures Short-Term Debt?

Genetic Signatures ASX:GSS -1.49% Short-Term Debt is A$0.47 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Genetic Signatures's Short-Term Debt for the quarter that ended in Dec. 2025 was A$0.47 Mil.

Genetic Signatures's quarterly Short-Term Debt declined from Dec. 2024 (A$0.42 Mil) to Jun. 2025 (A$0.00 Mil) but then increased from Jun. 2025 (A$0.00 Mil) to Dec. 2025 (A$0.47 Mil).

Genetic Signatures Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Genetic Signatures Short-Term Debt Related Terms

Genetic Signatures Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Genetic Signatures's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Signatures Short-Term Debt Chart

Genetic Signatures Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genetic Signatures Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.42 0.00 0.47
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of A$0.47 Mil mean?
Genetic Signatures (ASX:GSS) has a Short-Term Debt of A$0.47 Mil as of Dec. 2025.
Is Genetic Signatures' Short-Term Debt too high?
Genetic Signatures' current Short-Term Debt is A$0.47 Mil.
How does Genetic Signatures' Short-Term Debt compare to TMO and DHR?
Genetic Signatures' Short-Term Debt of A$0.47 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Diagnostics & Research company?
A good Short-Term Debt depends on the Medical Diagnostics & Research industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Genetic Signatures's current Short-Term Debt is A$0.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.38, compared to a current price of A$0.07 — trading 82.6% below its estimated fair value. The current Short-Term Debt is A$0.47 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current Short-Term Debt is A$0.47 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Signatures Business Description

Address 7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.